{"organizations": [], "uuid": "4ee43b5c15da48d45e980ef19a23e8f41331531d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180308.html", "section_title": "Archive News &amp; Video for Thursday, 08 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-jounce-therapeutics-q4-loss-per-sh/brief-jounce-therapeutics-q4-loss-per-share-0-29-idUSASB0C9DN", "country": "US", "domain_rank": 408, "title": "BRIEF-Jounce Therapeutics Q4 Loss Per Share $0.29", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.008, "site_type": "news", "published": "2018-03-08T19:38:00.000+02:00", "replies_count": 0, "uuid": "4ee43b5c15da48d45e980ef19a23e8f41331531d"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-jounce-therapeutics-q4-loss-per-sh/brief-jounce-therapeutics-q4-loss-per-share-0-29-idUSASB0C9DN", "ord_in_thread": 0, "title": "BRIEF-Jounce Therapeutics Q4 Loss Per Share $0.29", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "jounce therapeutics inc", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "thomson reuters trust principles", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 8 (Reuters) - Jounce Therapeutics Inc:\n* JOUNCE THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS\n* Q4 LOSS PER SHARE $0.29 * COLLABORATION REVENUE WAS $13.0 MILLION FOR Q4 OF 2017, COMPARED TO $20.3 MILLION\n* JOUNCE THERAPEUTICS - EXPECTS CASH BURN ON OPERATING EXPENSES AND CAPITAL EXPENDITURES FOR FULL YEAR 2018 TO BE APPROXIMATELY $80.0 MILLION TO $100.0 MILLION\n* EXPECTS TO RECORD APPROXIMATELY $50.0 MILLION TO $60.0 MILLION IN COLLABORATION REVENUE IN 2018\n* JOUNCE THERAPEUTICS - SEES EXISTING CASH, CASH EQUIVALENTS FUNDING OPERATING EXPENSES & CAPITAL EXPENDITURE REQUIREMENTS FOR AT LEAST NEXT 24 MONTHS Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-08T19:38:00.000+02:00", "crawled": "2018-03-09T14:05:23.021+02:00", "highlightTitle": ""}